Re­silience starts the year with its first deal out­side of North Amer­i­ca

Man­u­fac­tur­ing com­pa­ny Re­silience hit sev­er­al high points in 2022 in se­cur­ing an­oth­er fund­ing round and net­ting part­ner­ships with ma­jor play­ers, and now it’s start­ing the new year with a deal that moves it out­side North Amer­i­ca for the first time.

On Tues­day, Re­silience an­nounced that the Abu Dhabi-based sov­er­eign in­vestors, the Mubadala In­vest­ment Com­pa­ny, inked an eq­ui­ty in­vest­ment. The two par­ties will col­lab­o­rate on a bio­phar­ma man­u­fac­tur­ing plan to build a new man­u­fac­tur­ing fa­cil­i­ty in Abu Dhabi. As per the deal, Mubadala will es­tab­lish the fa­cil­i­ty and Re­silience will op­er­ate it. The Abu Dhabi fa­cil­i­ty will man­u­fac­ture a range of prod­ucts, in­clud­ing ther­a­pies for can­cer and in­fec­tious dis­eases, along with vac­cines and oth­er prod­ucts.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN